Dr Harriet Walter

Associate Professor of Medical Oncology and Honorary Consultant Medical Oncologist

School/Department: Genetics and Genome Biology, Department of

Telephone: +44 (0)116 258 7603



My clinical practice involves delivery of our Phase I portfolio across haematological malignancies and solid tumours. In addition I provide systemic treatments for the management of head and neck cancer. My research interests are in therapeutic drug development the design and delivery of early phase clinical trials and the development and assessment of novel therapies in B cell malignancies.


2020: MRC iCASE PhD studentship (Principle Investigator) 2020: Gilead UK & I Fellowship Programme Grant: £37315 (Principle Investigator). 2017-2020: CRUK Clinical Trial Fellowship: £95165.89 (Personal Fellowship). 2019-2022: LPMI/Hope PhD studentship: £50000 (Principle Investigator). 2019: Hope against Cancer & ECMC support: £ 21000 (Martin Dyer/Harriet Walter)- Single cell RNA-seq to assess mechanisms of therapeutic resistant in diffuse large B-cell lymphoma. 2017-2018: Hope against Cancer: £26500 (Martin Dyer/Harriet Walter)- Detection and assessment of circulating tumour DNA in patients with Diffuse Large B cell Lymphoma (DLBCL) as a predictive marker of residual disease or early relapse. 


(0) Danilov AV, Herbaux C, Walter HS, et al. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020;26(12):2810-2818. doi:10.1158/1078-0432.CCR-19-3504.
Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstram macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112-e121. doi:10.1016/S2352-3026(19)30210-8.
Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765-2775. doi:10.1182/blood-2019-01-896290
Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019; 104(2): e68-e71.
Walter HS, Trethewey C, Matthew J. Ahearne et al. Successful treatment of primary cutaneous diffuse large B cell lymphoma leg type with single agent venetoclax. JCO Precision Oncology.
Kozaki R, Vogler M, Walter HS et al. Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.  Cancers (Basel). 2018; 10(4): pii: E127.
Vogler M, Walter HS, Dyer MJS.  Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.  Br J Haematol. 2017; 178(3): 364-379.
Walter HS, Jayne S, Rule SA et al.  Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.  Blood. 2017; 129(20):2808-2810.
Walter HS, Jayne S, Mensah P et al.  Obinutuzumab-induced coagulopathy in chronic lymphocytic leukemia (CLL) with trisomy 12.  Blood Cancer Journal (2016) 6, e435; doi:10.1038/bcj.2016.42.
Walter HS, Salles GA, Dyer MJ. New agents to treat chronic lymphocytic leukemia. N Engl J Med. 2016; 374(22): 2185-2186.
Walter HS, Rule SA, Dyer MJ et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016; 127(4): 411-9.  



Novel therapies in the treatment of B cell malignancies


MSc Cancer Studies

Press and media

Novel therapies in the treatment of B cell malignancies


Medical Advisor for Cancer Research UK Centre for Drug Development. CRUK Clinical Trials Fellowship Grant Committee.


2018: College of Life Sciences PhD Prize 2017: Royal College of Physicians and National Institute for Health Research Trainee Award for contribution to research 2017-2018: European Hematology Association Clinical Research Training Award in Hematology (EHA CRTH)


Drug Development.


2003: BMedSci (Hons): Cellular pathology and Neuropharmacology (2.1). The University of Birmingham Medical School. 2006: MBChB with honours. The University of Birmingham Medical School. 2009: MRCP (United Kingdom). 2012: MSc Oncology (Distinction). Nottingham University. 2013: MRCP Specialty Certificate Examination in Medical Oncology. 2018: PhD. Studies of Bruton’s tyrosine kinase inhibitors in B-cell malignancies. Leicester Cancer Research Centre University of Leicester. 2020: AFHEA. 
Back to top
arrow-downarrow-down-3arrow-down-2arrow-down-4arrow-leftarrow-left-3arrow-left-2arrow-leftarrow-left-4arrow-rightarrow-right-3arrow-right-2arrow-right-4arrow-uparrow-up-3arrow-up-2arrow-up-4book-2bookbuildingscalendar-2calendarcirclecrosscross-2facebookfat-l-1fat-l-2filtershead-2headinstagraminstagraminstagramlinkedinlinkedinmenuMENUMenu Arrowminusminusrotator-pausec pausepinrotator-playplayc playplussearchsnapchatsnapchatthin-l-1thin-l-2ticktweettwittertwittertwitterwechatweiboweiboyoutubeyoutube